Loading organizations...
§ Private Profile · Boston, MA, USA
NuvoAir is a technology company.
NuvoAir develops an integrated specialty care platform that provides personalized heart and lung care through remote monitoring and tailored plans. The company combines proprietary hardware, software, and data analytics to offer continuous, proactive virtual care, enabling individuals to manage complex cardiopulmonary conditions and perform lung function tests from home. This comprehensive approach supports both patient engagement and provider insights into patient health.
The company was founded in 2016 by Lorenzo Consoli, who also serves as its CEO. Consoli established NuvoAir with the insight that technology could significantly transform cardiopulmonary care globally, initially launching operations in Europe before expanding its focus to the U.S. market to address specific healthcare needs there.
NuvoAir’s platform serves individuals living with various heart and lung conditions, alongside the healthcare providers who manage their care. The company's vision is to improve health outcomes by empowering both patients and clinicians with tools for better disease management, ultimately striving to reshape how chronic cardiopulmonary conditions are treated worldwide.
NuvoAir has raised $28.1M across 4 funding rounds.
NuvoAir has raised $28.1M in total across 4 funding rounds.
NuvoAir has raised $28.1M across 4 funding rounds. Most recently, it raised $11.0M Series A Extension in January 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 19, 2022 | $11M Series A Plus | Lana Ghanem | — | Announced |
| Jun 1, 2021 | $12M Series A | Albion VC | Amino Collective, Ananda Impact Ventures, LocalGlobe, Webtalk LTD, Industrifonden, Kaya, Novartis Pharma, Spiltan | Announced |
| Apr 17, 2019 | $3M Venture Round | Patrik Sobocki (msc, Phd) | Spiltan | Announced |
| Mar 30, 2017 | $2.1M Seed | Spiltan | — | Announced |
NuvoAir has raised $28.1M in total across 4 funding rounds.
NuvoAir's investors include Lana Ghanem, Albion VC, Amino Collective, Ananda Impact Ventures, LocalGlobe, Webtalk Ltd, Industrifonden, KAYA, Novartis Pharma, Spiltan, Patrik Sobocki (MSc, PhD).
NuvoAir is a digital health technology company specializing in respiratory care through virtual patient engagement and advanced remote monitoring solutions. It builds connected devices and software platforms, including Bluetooth-enabled spirometers and inhaler sensors, to serve patients with chronic respiratory diseases such as COPD, asthma, and chronic heart failure. NuvoAir’s technology empowers patients and clinicians with real-time data and AI-driven insights to improve diagnosis, treatment, and management of respiratory conditions, reducing urgent care visits by nearly 40% and enhancing patient quality of life[1][2][3].
Founded in 2016 in Stockholm and now headquartered in Boston, NuvoAir was inspired by the founder’s personal experience with childhood asthma. The company quickly gained traction by integrating human-led care with disruptive technology, expanding into clinical trial solutions and virtual care services. Key milestones include FDA clearance for home spirometry devices and raising $12 million in Series A funding in 2021, which accelerated its growth and innovation in AI-powered respiratory health monitoring[1][3][4].
NuvoAir rides the growing trend of digital health and remote patient monitoring, which has become critical due to the COVID-19 pandemic and the increasing prevalence of chronic respiratory diseases worldwide. The timing aligns with healthcare’s shift toward virtual care, AI integration, and patient empowerment, supported by rising demand for cost-effective, accessible chronic disease management. NuvoAir’s solutions influence the broader ecosystem by enabling decentralized clinical trials and enhancing collaboration between patients, clinicians, and pharma companies[2][4][5][6].
NuvoAir is positioned to expand its footprint in the US and global markets by advancing AI-native healthcare solutions and integrating with electronic medical records for population health management. Future trends shaping its journey include increased adoption of virtual care, AI-driven diagnostics, and personalized medicine. As it scales, NuvoAir’s influence may grow beyond respiratory care to broader chronic disease management, driving improved outcomes and operational efficiencies in healthcare systems worldwide[4][6][7].